Results 231 to 240 of about 4,840,656 (302)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Short-term clinical outcomes of balloon-assisted thrombectomy for acute middle cerebral artery occlusive. [PDF]

open access: yesFront Neurol
Liao B   +14 more
europepmc   +1 more source

The Ross Renaissance: Trends and Short-Term Outcomes of the Ross Procedure in the United States. [PDF]

open access: yesJACC Adv
Vadlakonda A   +6 more
europepmc   +1 more source

Short-Term Changes in Retinal Activity With Four Myopia Control Spectacle Lenses. [PDF]

open access: yesTransl Vis Sci Technol
Fernandes P   +3 more
europepmc   +1 more source

Tax certainty: proposals for the short term and the long term

open access: yesEconomics: Journal Articles, 2018
Santiago Díaz de Sarralde   +3 more
doaj  

Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.

open access: yesJAMA Netw Open
Grill JD   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy